Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.43 |
| ▸ | TUBB | P07437 | 4/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721861 | 0.77 | ACHE (0.65) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL16245222 | 0.76 | PKM (0.52) | CYP3A4MAPTCA9PTGS2CYP1A2 | |
| SCHEMBL171116 | 0.74 | ACHE (1.00) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL686849 | 0.74 | CYP1A2 (0.64) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL1402314 | 0.74 | ACHE (0.62) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL679526 | 0.73 | ACHE (0.60) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL8710437 | 0.72 | ACHE (0.59) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL58988 | 0.72 | ACHE (0.59) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL18472614 | 0.72 | ACHE (0.59) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL429756 | 0.72 | ACHE (0.59) | ACHECYP3A4MAPTCA9PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105017249-B | A kind of preparation method of the hydazone derivative of 1,2,4-triazole [4,3-α] pyridine ring | 浙江工业大学 | 2016-11-23 | — | — | CN | claimed |
| US-10730885-B1 | Coumarin derivatives | KING SAUD UNIVERSITY (SA) | 2020-08-04 | — | — | US | disclosed |
| CN-105017249-B | A kind of preparation method of the hydazone derivative of 1,2,4-triazole [4,3-α] pyridine ring | 浙江工业大学 | 2016-11-23 | — | — | CN | disclosed |
| EP-3041904-A1 | STYRYL SULFIDE DYES | BASF SE (DE) | 2016-07-13 | — | — | EP | disclosed |
| WO-2015028543-A1 | STYRYL SULFIDE DYES | BASF SE (DE) | 2015-03-05 | — | — | WO | disclosed |
| US-6413962-B1 | ANESTHESIA AND TEMPERATURES REDUCTION; ALPHA-ADRENOCEPTOR AGONIST; RESTORATIVE TO CENTRAL NERVOUS SYSTEM, ESPECIALLY MOTOR AND SENSORY FUNCTIONAL LOSSES FROM TRAMATIC SPINAL CORD INJURIES; ANTISPASTICS; NONSEDATIVE; SIDE EFFECT REDUCTION | NAFTCHI N ERIC (US) | 2002-07-02 | — | — | US | disclosed |
| US-6133305-A | PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISORDERS SUCH AS CANCER | SUGEN, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| WO-1998043649-A2 | AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B¿6? | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-08 | — | — | WO | disclosed |
| CN-1034864-C | Maillard reaction inhibitor | OTSUKA PHARMA CO LTD (JP) | 1997-05-14 | — | — | CN | disclosed |
| US-5422360-A | Hydrazonoimidazolidin-4-one derivatives; treatment of diabetes and aging disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-06 | — | — | US | disclosed |
| EP-0531812-A1 | Maillard reaction inhibitor, process for producing it, composition containing it and the use thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
| CN-1069728-A | Maillard reaction inhibitor | OTSUKA PHARMA CO LTD (JP) | 1993-03-10 | — | — | CN | disclosed |
| US-4992347-A | Marking | COURTAULDS PLC (GB) | 1991-02-12 | — | — | US | disclosed |
| EP-0301057-A1 | Forming a permanent image in a layer | COURTAULDS PLC (GB) | 1989-02-01 | — | — | EP | disclosed |
| WO-1988006306-A1 | MARKING | COURTAULDS PLC (GB) | 1988-08-25 | — | — | WO | disclosed |
| EP-0279600-A1 | Marking | COURTAULDS PLC (GB) | 1988-08-24 | — | — | EP | disclosed |
| US-4178382-A | INSECTICIDE FOR COTTON | UNIROYAL, INC. (US) | 1979-12-11 | — | — | US | disclosed |
| US-4052553-A | BACTERICIDE, ANTIMALARIAL | BURROUGHS WELLCOME CO. (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730885-B1 | Coumarin derivatives | CBR3, KCNH1, CBR1 | ACHE 2704/4885CYP3A4 113/4885MAPT 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.